Don't think govt will give relaxation to Rohingya Muslims: Naqvi

Agencies
September 9, 2017

Patna, Sep 9: It would be difficult for the government to offer any relaxation to Rohingya Muslims, who have fled Myanmar, Union Minority Affairs Minister Mukhtar Abbas Naqvi said here today.

The matter is pending before the Supreme Court and the government is also looking into it, Naqvi said at the Parliamentarian Conclave here.

"But I do not think we will be able to give any relaxation to them (Rohingya Muslims) when their nation has refused to keep them," he said.

The Supreme Court had on September 4 sought the view of the government on a petition challenging its decision to deport illegal Rohingya Muslim immigrants back to Myanmar. The matter has been posted for September 11.

Union minister Kiren Rijiju had on Tuesday said the Rohingya people are illegal immigrants and stand to be deported.

Violent attacks allegedly by Myanmarese armymen have led to an exodus of Rohingya tribals from the western Rakhine state in that country to India and Bangladesh.

Many of them, who had fled to India after a spate of violence earlier, have settled in Jammu, Hyderabad, Haryana, Uttar Pradesh, Delhi-NCR and Rajasthan.

On the Uniform Civil Code, Naqvi said the government believes in moving ahead on the issue after evolving a consensus.

The Constitution has clearly stated that the State should evolve a consensus for the implementation of the UCC, he said, adding that the Law Commission had also sought the opinion of various stakeholders on the issue.

The minister said the appeasement policy had hijacked the empowerment of minorities in the last several decades and that the Centre had adopted the policy of "empowerment without appeasement".

This has ensured socio-economic-educational empowerment of poor sections of minority communities in the last three years, Naqvi said.

Providing basic amenities in minority concentrated areas has been the governments priority in the last three years, he said. 

Comments

Mohammed SS
 - 
Sunday, 10 Sep 2017

Indian government will do something for Muslims..?, is it a Joke..? And Mr. Naqvi you are a tattoo of BJP/RSS, have you ever supported Muslims of your country before..? if you have little common sence you hve to support your brothers, Beware very soon you will pay for it.

mohammad.n
 - 
Sunday, 10 Sep 2017

well said naqvi. Bjp is pleased with you. Anyways rohingya no need to expect much from indian bjp govt as minorities citizens are already suffering in india. 

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
May 3,2020

Bengaluru, May 3: Renowned Kannada poet KS Nissar Ahmed passed away on May 3.

Winner of several awards including Karnataka Sahitya Akademi Award for Poetry, Rajyotsava Award, Padma Shri among others, Ahmed died at the age of 84

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
March 10,2020

Mangaluru, Mar 10: Four airports which are run by the Airport Authority of India (AAI), including Mangaluru International airport, have been adjudged among the best aerodromes in the world, winning 10 awards in four different categories at the 2019 ASQ awards.

ASQ is a globally established programme that measures passengers’ satisfaction while traveling through an airport. Airports Council International (ACI), which is an independent agency of airport operators, carries out international benchmarking of aerodromes.

“Four AAI airports — Chandigarh, Mangaluru, Trivandrum and Lucknow — have been adjudged the best in the world in recently announced 2019 ASQ awards. These airports won 10 awards in four categories,” Airports Authority of India (AAI) said in a release here on Tuesday.

The survey measures passengers’ satisfaction across 34 key performance indicators that include eight major categories such as access, check-in, security, airport facilities, food and beverage, retail, airport environment and arrival services.

The four categories in which these airports bagged the best airport awards were size and region, environment and ambiance, customer service and infrastructure and facilitation, as per the AAI.

The survey was carried out at across 356 airports across North America, Latin America and the Caribbean, Europe, Africa, the Middle East, and Asia.

The survey results are monitored by airport tariff regulator AERA, NITI Aayog, and civil aviation Ministry, the release added.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
March 4,2020

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.